AVTR enters the final days of September with a quietly improving technical setup. Short sellers have been cutting positions for a month, the borrow market has swung from tight to remarkably open, and a UBS target upgrade sits above the current price. The question for the October 30 earnings print is whether the recovery narrative can hold.
The most striking shift in recent weeks is in the lending market, and it runs in the bulls' favour. Availability has surged to 3,790%, meaning there are roughly 38 shares available to borrow for every one already lent out. That compares with around 1,240% in mid-September, when availability was at its tightest of the past 30 days. The borrow pool has effectively flooded open. Cost to borrow has followed suit, easing to 0.44% after a gentle slide through the week, though it edged up 11% over the past month. There is no squeeze pressure here. Short interest has also drifted lower: at 7.2% of the free float, it has fallen roughly 4.4% over the past month, with the FINRA fortnightly count confirming about 51.4 million shares short as of mid-September. The ORTEX short score of 47 sits in a broadly neutral zone and has been range-bound for two weeks, reflecting the absence of any fresh catalyst driving new short conviction.
Options tell a slightly more cautious story, though the signal is modest rather than extreme. The put/call ratio has climbed to 0.087, about 1.4 standard deviations above its 20-day average of 0.067. That is a noticeable move relative to recent history, but the absolute level remains low. For most of August and early September the ratio was hugging 0.055 to 0.056, before stepping up around September 21. The 52-week high on the PCR is 12.7, so current positioning is nowhere near a genuine defensive extreme. The options market looks mildly more cautious than it was a fortnight ago, not alarmed.
The analyst picture is mixed, but the direction of travel since the July earnings beat has been upward. After AVTR jumped 11.6% on its Q2 result, most covering firms raised targets: Morgan Stanley moved to $14, RBC to $14, Stifel to $15, Wells Fargo to $16. Then in early September UBS lifted its target to $16.00 from $10.50, the most aggressive single move in the recent round, while holding a Neutral rating. The consensus remains a "buy" by count, but several of the largest firms by coverage are neutral or below: Barclays kept an Underweight with an $8 target as recently as June, and Evercore sits at In-Line with a $14 target. The mean price target of $14.56 is slightly below the current price of $15.24, a flag worth noting. The stock has run past consensus in the two months since the beat, and the Street has not yet caught up. The bull case centres on recovery in the laboratory solutions segment and an expected return to positive organic growth in bioscience production. Bears point to continued customer losses and a growth rate that may lag peers even in a recovery scenario.
Retail attention has picked up. Wikipedia page views for Avantor are running more than two standard deviations above their 90-day average, according to ORTEX Alt Data (as of September 22). That is an attention signal, not a revenue indicator, but it does suggest the name is drawing more interest than usual from non-institutional audiences, possibly connected to the broader biopharma sector recovery narrative.
Ownership concentration is notable. Dodge and Cox holds 17.7% of shares, a dominant position for a passive-style manager, and added roughly 372,000 shares in the quarter to June. BlackRock has been the more active buyer recently, adding 4.6 million shares through August. Marshall Wace and AQR, both quantitative shops, added 9.7 million and 6.7 million shares respectively in the period, suggesting momentum-driven positioning has been building alongside the fundamental holders. No 13D activist is on the register. Inside the company, the only recent open-market purchase on EDGAR was a director buying 10,000 shares at $8.32 in May. The September CFO activity was a compensation grant, not a discretionary buy.
With earnings 30 days out, the focus will be on whether the bioscience production segment delivers its first positive organic growth quarter as management has guided, and whether laboratory solutions can sustain its recovery. The July print produced an 11.6% single-day gain; the prior quarter delivered a 1.4% decline. That range of outcomes, and the stock now trading above the analyst consensus target, makes the setup for the October 30 release less straightforward than the positioning data alone might suggest.
See the live data behind this article on ORTEX.
Open AVTR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
